Cited by 122Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesImmune cells in cancer

Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy

Open access
Guo, Liang, Wang, Chuanlei, Qiu, Xiang, Pu, Xiaoyu, Chang, Pengyu·2020·Frontiers in Immunology

Abstract

Colorectal cancer occurrence and progression involve multiple aspects of host immune deficiencies. In these events, immune cells vary their phenotypes and functions over time, thus enabling the immune microenvironment to be "tumor-inhibiting" as well as "tumor-promoting" as a whole. Because of the association of tumoricidal T cell infiltration with favorable survival in cancer patients, the Immunoscore system was established. Critically, the tumoral Immunoscore serves as an indicator of CRC patient prognosis independent of patient TNM stage and suggests that patients with high Immunoscores in their tumors have prolonged survival in general. Accordingly, stratifications according to tumoral Immunoscores provide new insights into CRC in terms of comparing disease severity, forecasting disease progression, and making treatment decisions. An important application of this system will be to shed light on candidate selection in immunotherapy for CRC, because the T cells responsible for determining the Immunoscore serve as responders to immune checkpoint inhibitors. However, the Immunoscore system merely provides a standard procedure for identifying the tumoral infiltration of cytotoxic and memory T cells, while information concerning the survival and function of these cells is still absent. Moreover, other infiltrates, such as dendritic cells, macrophages, and B cells, can still influence CRC prognosis, implying that those might also influence the therapeutic efficacy of immune checkpoint inhibitors. On these bases, this review is designed to introduce the Immunoscore system by presenting its clinical significance and application in CRC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.01052

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PD-L1 expression can vary heterogeneously within different regions of a tumor, while metastatic CRC lesions may exhibit varying immunoscores.

    “This is because PD-L1 expression can vary heterogeneously within different regions of a tumor, while metastatic CRC lesions may exhibit varying immunoscores [163,164].”
  • Assessing the densities of T and B cells within CRC tumors offers higher accuracy compared to evaluating PD-L1 expression alone in predicting the efficacy of immunotherapy.

    “Recent findings suggest that assessing the densities of T and B cells within CRC tumors offers higher accuracy compared to evaluating PD-L1 expression alone in predicting the efficacy of immunotherapy.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 103 · Cited by 122

Research works printed but not linked: 1

  1. [31]Carducci MA Giblin J Dottellis D 2019 ASCO Annual Meeting Proceedings. J Clin Oncol. (2019) 37: 192s.

Authors
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P.
Affiliations
  • First Hospital of Jilin University (CN)
  • Jilin University (CN)
Corresponding author
Chang, Pengyu
Venue
Frontiers in Immunology
Published
2020-05-28
Volume
11
Pages
1052-1052
ISSN
1664-3224 (ISSN-L)
OpenAlex
W3032704329
Cited by
122
References
103
Citations by year
2026: 13 · 2025: 22 · 2024: 25 · 2023: 17 · 2022: 29 · 2021: 12 · 2020: 4
FWCI
1.66
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81874254)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
colorectal cancer, tumor immune microenvironment, immune score, tumor-infiltrating lymphocytes, cytotoxic T lymphocytes, memory T cells, prognostic factors, immune checkpoint inhibitors, immunotherapy response, dendritic cells, tumor-associated macrophages, B cells, patient stratification
MeSH terms
B-Lymphocytes, Dendritic Cells, Humans, Immunotherapy, Killer Cells, Natural, Macrophages, Neoplasm Staging, Prognosis, T-Lymphocytes, Cytotoxic, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Models, Immunological, T-Lymphocytes, Regulatory, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review